Home > Newsletters > Drug Industry Daily > Drugmakers to Pay User Fees for EMA’s New Pharmacovigilance Duties
Drug Industry Daily
June 20, 2012 | Vol. 11 No. 121
Drugmakers to Pay User Fees for EMA’s New Pharmacovigilance Duties
As EU pharmacovigilance legislation takes effect in early July, the European Commission (EC) is outlining how much drugmakers will have to pay for the European Medicines Agency (EMA) to take on the postmarket regulations, according to a new concept paper.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.